跳转至内容
Merck
CN

252790

Sigma-Aldrich

3-Deazaneplanocin A hydrochloride

≥97% (HPLC), solid, EZH2 inhibitor, Calbiochem®

别名:

组蛋白甲基转移酶EZH2抑制剂,DZNep

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C12H14N4O3 · xHCl · yH2O
化学文摘社编号:
分子量:
262.26 (anhydrous free base basis)
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

组蛋白甲基转移酶EZH2抑制剂,DZNep, Histone Methyltransferase EZH2 Inhibitor, DZNep, CAS 120964-45-6, is a cell-permeable inhibitor of EZH2-mediated trimethylation of K27 on histone H3.

质量水平

方案

≥97% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
desiccated (hygroscopic)
protect from light

颜色

tan

溶解性

DMSO: 10 mg/mL

运输

wet ice

储存温度

−20°C

SMILES字符串

Cl.[n]2(c3c(nc2)c(ncc3)N)[C@H]1[C@@H]([C@@H](C(=C1)CO)O)O

InChI

1S/C12H14N4O3.ClH/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19;/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14);1H/t8-,10-,11+;/m1./s1

InChI key

UNSKMHKAFPRFTI-FDKLLANESA-N

一般描述

一种细胞可渗透的化合物,显示(在1 µM浓度下)可抑制EZH2介导的组蛋白H3上K27的三甲基化,并诱导细胞周期调节基因(p21和p27)以及细胞死亡调节剂(FBXO32)在OCI-AML3和HL-60细胞上的表达,其中用抑制剂处理可增加两种培养物中前者的p16水平,但不会增加后者的p16水平。在200 nm至2000 nm的浓度下,发现该化合物剂量依赖性地消耗了培养的和原代AML细胞提取物中多梳家族蛋白EZH2、SUZ12和EED的表达。 在高达≥1000 nM的浓度下,DZNep剂量依赖性地将凋亡细胞的百分比增加> ~ 38%,与HL-60培养物相比,对OCI-AML3的效力更高,并且对两种细胞系的菌落生长抑制> ~ 85%。在OCI-AML3培养物中,1000 nM的处理表明细胞周期的G0/G1期(58.5%)的细胞积累显著增加,而细胞周期的S期(35.2%)和G2/M期(6.3%)的细胞数量随之减少。当与panobinostat(PS)共同处理时,显示200 nM至1000nM DZNep比单独的DZNep更有效地降低OCI-AML3和HL-60培养物中的细胞活力,呈剂量依赖性。与单独使用任一化合物治疗相比,DZNep(1mg/kg,每周两次,腹膜内)和PS显著延长了植入HL-60细胞的小鼠的存活期。DZNep也是一种已知的S-腺苷-L-同型半胱氨酸(AdoHcy)水解酶抑制剂。也可以25 mM的H2O溶液(目录号506069)提供。

包装

用惰性气体包装

外形

以盐酸盐形式提供。

制备说明

复溶后,分装并冷冻保存(-20°C)。储备液在-20°C条件下可稳定保存3个月。

其他说明

Fiscus, W., et al. 2009.Blood13, 2733.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

毒性:标准处理(A)

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Xiaoxia Su et al.
Journal of cellular and molecular medicine, 26(2), 375-384 (2021-12-08)
Oxidative stress, a hallmark of ageing, inhibits the osteogenic differentiation of bone marrow-derived mesenchymal stem cells in long bone. The dysfunction of the cellular antioxidant defence system is a critical cause of oxidative stress, but the mechanism of the decline

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持